CN103957709A - Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合 - Google Patents

Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合 Download PDF

Info

Publication number
CN103957709A
CN103957709A CN201280036936.9A CN201280036936A CN103957709A CN 103957709 A CN103957709 A CN 103957709A CN 201280036936 A CN201280036936 A CN 201280036936A CN 103957709 A CN103957709 A CN 103957709A
Authority
CN
China
Prior art keywords
group
alkyl
amino
aryl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036936.9A
Other languages
English (en)
Chinese (zh)
Inventor
阿里吉特·查克拉瓦蒂
帕特里克·文森特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Millennium Pharmaceuticals Inc
Original Assignee
Takeda Pharmaceutical Co Ltd
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Millennium Pharmaceuticals Inc filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN103957709A publication Critical patent/CN103957709A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280036936.9A 2011-06-03 2012-06-04 Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合 Pending CN103957709A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161493217P 2011-06-03 2011-06-03
US61/493,217 2011-06-03
US201261613207P 2012-03-20 2012-03-20
US61/613,207 2012-03-20
PCT/US2012/040733 WO2012167247A1 (en) 2011-06-03 2012-06-04 Combination of mek inhibitors and selective inhibitors of aurora a kinase

Publications (1)

Publication Number Publication Date
CN103957709A true CN103957709A (zh) 2014-07-30

Family

ID=47259953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036936.9A Pending CN103957709A (zh) 2011-06-03 2012-06-04 Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合

Country Status (9)

Country Link
US (1) US9629850B2 (https=)
EP (1) EP2713727B1 (https=)
JP (2) JP6263468B2 (https=)
CN (1) CN103957709A (https=)
AR (1) AR086656A1 (https=)
CA (1) CA2837724C (https=)
TW (1) TW201316991A (https=)
UY (1) UY34114A (https=)
WO (1) WO2012167247A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
CN103408551B (zh) * 2013-07-25 2015-08-05 苏州明锐医药科技有限公司 阿立塞替的制备方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
JP7253181B2 (ja) * 2018-12-21 2023-04-06 株式会社Ｎｔｔドコモ 情報処理装置、情報処理方法及びプログラム
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220032607A (ko) * 2020-02-27 2022-03-15 국립대학법인 홋가이도 다이가쿠 항암제를 스크리닝하는 방법 및 췌장암 치료를 위한 키나아제 억제제의 조합 의약
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014603A (zh) * 2004-05-14 2007-08-08 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
US20080045501A1 (en) * 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CN101679411A (zh) * 2006-12-20 2010-03-24 武田药品工业株式会社 Mapk/erk激酶抑制剂
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540987T3 (es) 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
US20100125138A1 (en) 2008-11-18 2010-05-20 Takeda Pharmaceutical Company Limited PROCESS FOR MAKING (R)-3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES THEREOF
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014603A (zh) * 2004-05-14 2007-08-08 千禧药品公司 通过抑制极光激酶抑制有丝分裂的化合物和方法
US20080045501A1 (en) * 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CN101679411A (zh) * 2006-12-20 2010-03-24 武田药品工业株式会社 Mapk/erk激酶抑制剂
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合

Also Published As

Publication number Publication date
EP2713727A1 (en) 2014-04-09
TW201316991A (zh) 2013-05-01
AR086656A1 (es) 2014-01-15
CA2837724C (en) 2019-10-29
EP2713727B1 (en) 2021-03-31
EP2713727A4 (en) 2014-10-22
US9629850B2 (en) 2017-04-25
CA2837724A1 (en) 2012-12-06
WO2012167247A1 (en) 2012-12-06
JP6263468B2 (ja) 2018-01-17
US20140336180A1 (en) 2014-11-13
JP2014516992A (ja) 2014-07-17
JP2017178969A (ja) 2017-10-05
UY34114A (es) 2013-01-03

Similar Documents

Publication Publication Date Title
JP6263468B2 (ja) Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ
JP5102839B2 (ja) 有糸分裂進行を阻害するための化合物
AU2009330727B2 (en) Combination of Aurora kinase inhibitors and anti-CD20 antibodies
BR112020022148A2 (pt) Métodos de tratamento de câncer
WO2022051567A1 (en) Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions
CN119768393A (zh) Mek抑制剂和其用途
CN116261455A (zh) 一种药物组合物及其在治疗癌症中的用途
US10213436B2 (en) Methods of treating cancer using aurora kinase inhibitors
CA3239728A1 (en) Methods of treating cancer
WO2023149450A1 (ja) Ｍａｌｔ１阻害薬を有効成分として含むがん治療剤
MX2008001971A (es) Combinacion de compuestos organicos.
HK1196296B (en) Combination of mek inhibitors and selective inhibitors of aurora a kinase
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140730

WD01 Invention patent application deemed withdrawn after publication